Business
NIHR i4i award
NIHR i4i award.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n RNS Number : 5134F\n Physiomics PLC\n 10 March 2020\n \n \n \n \n 10 March 2020\n \n \n \n \n \n Physiomics plc \n \n \n (\"Physiomics\") or (the \"Company\")\n \n \n \n NIHR i4i award\n \n \n \n \n Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a \"Connect\" award by the National Institute for Health Research (\"NIHR\") Invention for Innovation (\"i4i\") programme in respect of the Company's continued development of its tool for use in personalised treatment of cancer.\n \n The title of the award project is \"Further development of and evidence generation for a precision dosing tool for optimising chemotherapy dosing in advanced prostate cancer (NIHR201282)\". The award, which is funded by the UK Department of Health & Social Care, will provide 100% reimbursement of project costs of up to £150,000, over an anticipated 12-month period, starting in April 2020, with no matched funding required from Physiomics.\n \n The project will build on the Company's successful work to date in developing its personalised oncology tool, that has been funded mainly through Innovate UK grants in 2017 and 2018. In particular, the 2018 Innovate UK grant enabled the Company to develop a demonstrator version of a decision support tool to help clinicians treating late-stage prostate cancer to optimise the dosing of docetaxel, a commonly used chemotherapy.\n \n Personalised treatment of prostate cancer - progress to date\n Prostate cancer represents around 13% of all new cancers, with around 50,000 new cases diagnosed each year in the UK and 170,000 in the USA. Of these, 20-30% of patients present with late stage metastatic disease, where 5-year survival is below 30%. In these patients, docetaxel is commonly used as a first line chemotherapy. Variations between individuals in blood levels of the drug have been observed within a 2-3-fold range for the same administered dose level(1), potentially leading to a significant number of patients being either under or over-dosed. Exposure-controlled dosing, relying on pharmacokinetic or proxy biomarker measurements, ha...